Homayoun Amin, MD
Cardiovascular Disease · McDonough, GANPI 1982645198
Payments from drug & device makers
Across 421 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novartis$819
- Pfizer$719
- Johnson & Johnson$646
- Amarin Pharma, Inc.$618
- Merck$406
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,74197%
- Education$2263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 73 | $1,307 |
| Novartis | 56 | $819 |
| Pfizer | 37 | $719 |
| Johnson & Johnson | 50 | $646 |
| Amarin Pharma, Inc. | 38 | $618 |
| Merck | 23 | $406 |
| E.r. Squibb & Sons, L.L.C. | 35 | $300 |
| AstraZeneca(2 entities) | 11 | $296 |
| Actelion Pharmaceuticals US, Inc. | 16 | $242 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $207 |
| Astellas Pharma US Inc | 5 | $164 |
| Boehringer Ingelheim | 9 | $146 |
| Esperion Therapeutics, Inc. | 6 | $128 |
| Alnylam Pharmaceuticals Inc. | 5 | $120 |
| Abbott | 4 | $99 |
| Arbor Pharmaceuticals, Inc. | 6 | $87 |
| Abiomed | 3 | $81 |
| Edwards Lifesciences | 3 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Scpharmaceuticals Inc. | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Bayer | 2 | $32 |
| Vital Connect, Inc | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $27 |
| Boston Scientific | 1 | $27 |
| Novo Nordisk | 2 | $25 |
| G Medical Diagnostic Services, Inc. | 2 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $19 |
| Normatec Industries, LP | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Gilead | 1 | $16 |
| CMP Pharma, Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$478
How this compares
$6,967 in reported general payments places this provider in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 332 | $381,929 |
| Repatha SureclickEvolocumab | 275 | $195,138 |
| JardianceEmpagliflozin | 99 | $90,075 |
| EntrestoSacubitril/Valsartan | 72 | $76,417 |
| XareltoRivaroxaban | 52 | $60,090 |
| FarxigaDapagliflozin Propanediol | 30 | $31,798 |
| Praluent PenAlirocumab | 35 | $24,660 |
| Metoprolol Succinate | 1,183 | $13,152 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 25 | $9,586 |
| VascepaIcosapent Ethyl | 33 | $7,989 |
| Atorvastatin Calcium | 642 | $4,568 |
| Amlodipine Besylate | 971 | $3,920 |
| Rosuvastatin Calcium | 351 | $3,376 |
| Ezetimibe | 189 | $2,979 |
| Losartan Potassium | 391 | $2,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $719 | $381,929332 claims |
| Boehringer IngelheimJardiance | $146 | $90,07599 claims |
| NovartisEntresto | $819 | $76,41772 claims |
| Johnson & JohnsonXarelto | $646 | $60,09052 claims |
| AstraZenecaFarxiga | $296 | $31,79830 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $87 | $9,58625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in McDonough
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
- Michael MorrisAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.